|
|
Post by krj00 on Jan 2, 2014 14:12:58 GMT -5
and a positive catalyst in FDA approval, and a partner with upfront money,does Mannkind have enough cash to get there without further dilution?
|
|
|
|
Post by alcc on Jan 2, 2014 14:28:52 GMT -5
Yes. That's the rationale behind the expensive Deerfield deal, in addition to repayment of the note due in December. The company's internal planning I am sure assumes no deal before approval -- nor do I. I know my speculation is as good (bad) as the next guy's; however, given the amount of time that has passed when they signed Greenhills to shop for a deal, my read is that interested BPs, if any, have decided to wait for approval. If I were the BP, I know I would. Of course, now that I've said it, they will announce a deal next week!
|
|
|
|
Post by babaoriley on Jan 2, 2014 18:58:33 GMT -5
If MNKD turns into one half the company we think it will, the deal should be done before PDUFA. And the reason is multiple BP's (say three) interested, and in competition, they should agree to a deal now, with relatively little up front money (unrefundable), with the bulk of up front money paid upon approval. That way, the BP can begin to prepare for the expected launch. In competitive bidding, I would expect something like that to happen, if no competitive bidding, well...
|
|
